loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Enzastaurin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Enzastaurin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations
    Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations

    13 Oct 2022

    // ACCESSWIRE

    https://www.accesswire.com/720110/Aytu-BioPharma-Announces-Strategic-Shift-to-Focus-on-Commercial-Operations-and-Indefinite-Suspension-of-Clinical-Development-Programs

    ACCESSWIRE
    13 Oct 2022
    Share Share
    Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
    Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin

    16 Aug 2022

    // ACCESSWIRE

    https://www.accesswire.com/712255/Aytu-BioPharma-Announces-Issuance-of-Its-First-Patent-for-AR101Enzastaurin

    ACCESSWIRE
    16 Aug 2022
    Share Share
    FDA Approves & Grants ODD to Aytu's Enzastaurin in VEDS
    FDA Approves & Grants ODD to Aytu's Enzastaurin in VEDS

    14 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/denovo-biopharma-llc-announces-partner-aytu-biopharma-receives-fda-clearance-and-orphan-drug-designation-for-enzastaurin-in-vascular-ehlers-danlos-syndrome-301444292.html

    PRNEWSWIRE
    14 Dec 2021
    Share Share
    First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102
    First Patient Dosed in Biomarker-Guided Phase 3 Study of DB102

    08 Jan 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-dosed-in-biomarker-guided-phase-3-study-of-db102-enzastaurin-in-patients-with-newly-diagnosed-glioblastoma-gbm-301202417.html

    PRNEWSWIRE
    08 Jan 2021
    Share Share
    Enterprise Therapeutics Awarded up to £5.7M from Cystic Fibrosis Foundation
    Enterprise Therapeutics Awarded up to £5.7M from Cystic Fibrosis Foundation

    16 Oct 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191015005477/en

    BUSINESSWIRE
    16 Oct 2019
    Share Share
    First Patient Dosed In Pivotal Phase 3 Study Of First Line Therapy for DLBCL
    First Patient Dosed In Pivotal Phase 3 Study Of First Line Therapy for DLBCL

    03 Apr 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-dosed-in-pivotal-biomarker-guided-phase-3-study-of-first-line-therapy-with-db102-enzastaurin--r-chop-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-dlbcl-300623879.html

    PR NEWSWIRE
    03 Apr 2018
    Share Share